Artiva Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
ARTV$4.06-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| THREE MONTHS ENDED MARCH 31, | ||
|---|---|---|
| 2025 | 2024 | |
| License and development support revenue (including related party amounts of $0 and $251, respectively) | $— | $251 |
| Operating expenses: | ||
| Research and development (including related party amounts of $23 and $288, respectively) | 17,052 | 11,156 |
| General and administrative | 5,119 | 3,587 |
| Total operating expenses | 22,171 | 14,743 |
| Loss from operations | (22,171) | (14,492) |
| Other income, net: | ||
| Interest income | 1,864 | 650 |
| Change in fair value of SAFEs (including related party amounts of $0 and $(217), respectively) | — | (268) |
| Other income (expense) | (4) | 147 |
| Total other income, net | 1,860 | 529 |
| Net loss | $(20,311) | $(13,963) |
| Net loss per share, basic and diluted: | $(0.83) | $(17.24) |
| Weighted-average common shares outstanding, basic and diluted | 24,341,978 | 809,758 |
| Comprehensive loss: | ||
| Net loss | $(20,311) | $(13,963) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investments, net | 129 | (101) |
| Comprehensive loss | $(20,182) | $(14,064) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.